Private placement yields $2.5 million from the sale of Veris Health common stock at a $35 million pre-money valuation. NEW YORK , June 24, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiary, Veris Health Inc. ("Veris"), today announced... Read More

Long-term strategic partnership and commercial transition follow successful completion of pilot program of Veris Cancer Care Platform™ at OSUCCC – James NEW YORK , June 3, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health... Read More

Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Veris Health completed 1Q25 financing, resumed development of implantable physiological monitor, and will soon launch first commercial partnership with major cancer center PAVmed seeking to leverage infrastructure and expand into biopharma sector; actively evaluating clinical and late... Read More

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , May 1, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, May 15, 2025 , at 8:30 AM ET . During the call,... Read More

Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commercial insurance coverage policies Veris Health secured financing to resume advancement of implantable physiological monitor through FDA clearance and commercial launch PAVmed completed debt restructuring and Lucid deconsolidation to regain Nasdaq compliance and strengthen balance sheet Conference call and... Read More

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , March 11, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Tuesday, March 25, 2025 , at 8:30 AM ET . During the... Read More

Gross proceeds of approximately $2.4 million from sale of PAVmed securities priced at-the-market and Veris common stock priced at a $35 million pre-money valuation NEW YORK , Feb. 24, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiary,... Read More

NEW YORK , Feb. 18, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that on February 14 , 2025, PAVmed received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has... Read More

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , Oct. 31, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, November 14, 2024 , at 8:30 AM ET . During the... Read More

Grant will fund research to optimize Veris Cancer Care Platform for medically underserved cancer patients, in partnership with an academic cancer center NEW YORK , Oct. 10, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health... Read More

Efforts include appointment of seasoned biotech investor Sundeep Agrawal , M.D. to board to replace departing directors NEW YORK , Sept. 16, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that, as part of its efforts to regain compliance with... Read More

Study demonstrates excellent analytical accuracy, repeatability, and reproducibility of the assay NEW YORK , Aug. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the peer-reviewed publication of an analytical validation study of its EsoGuard ® Esophageal DNA... Read More

Lucid reports record quarterly EsoGuard ® test volume and held productive meeting with CMS Medicare Administrative Contractor (MAC) Palmetto GBA's MolDX Program Veris Health actively pursuing financing following launch of pilot program with The Ohio State's James Cancer Hospital Conference call and webcast to be held today, August 13 th at 8:30 AM EDT NEW YORK , Aug. 13, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ)... Read More

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , July 30, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Tuesday, August 13, 2024 , at 8:30 AM ET . During the... Read More

First patients enrolled on the Veris Cancer Care Platform NEW YORK , June 13, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that Veris and The Ohio State University... Read More

Lucid strengthens balance sheet and secures a July 17, 2024 MolDX pre-submission meeting date Veris Health completes MOU with The Ohio State's James Cancer Hospital Conference call and webcast to be held tomorrow, May 14 th at 8:30 AM EDT NEW YORK , May 13, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical... Read More

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , May 3, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Tuesday, May 14, 2024 , at 8:30 AM ET . During the call,... Read More

Parties to implement a pilot program of the Veris Cancer Care Platform NEW YORK , April 30, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that Veris and The Ohio State... Read More

Lucid's quarterly revenue increased 33 percent sequentially Launched wholly-owned incubator, PMX, to complete development and commercialization of existing portfolio technologies Conference call and webcast to be held tomorrow, March 27 th at 8:30 AM ET NEW YORK , March 26, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating... Read More

The incubator, PMX, and medical device firm Hatch Medical, execute joint venture agreement to complete their development and commercialization, starting with PortIO NEW YORK , March 21, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has... Read More

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , March 13, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Wednesday, March 27, 2024 , at 8:30 AM ET . During the... Read More

Studies demonstrate real-world clinical utility of EsoGuard testing to detect esophageal precancer NEW YORK , Dec. 12, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that three manuscripts providing interim results from the P... Read More

PAVmed shareholders as of January 15, 2024 will participate in distribution of approximately 3.3 million shares of Lucid common stock 1-for-15 reverse stock split to be effective as of market open on December 7, 2023 NEW YORK , Dec. 4, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics,... Read More

Lucid's quarterly revenue increased 392 percent sequentially Veris Health commercial expansion efforts underway, with next-generation Veris Cancer Care Platform launching in Q4 Conference call and webcast to be held tomorrow, November 15 th at 8:30 AM EST NEW YORK , Nov. 14, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating... Read More

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , Nov. 1, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Wednesday, November 15, 2023 , at 8:30 AM EST . During... Read More

NEW YORK , Sept. 21, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or "Lucid Diagnostics"), a commercial-stage cancer prevention diagnostics company, today announced their participation in the... Read More

Study documents 100 percent concordance between EsoGuard ® test results and subsequent medical decision-making Timely results support recently proposed federal legislation which seeks to fund guaranteed fire fighter access to early detection tests such as EsoGuard NEW YORK , Sept. 6, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics... Read More

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , July 31, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Wednesday, August 16, 2023 , at 8:30 AM EST . During... Read More

Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , July 31, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Tuesday, August 15, 2023 , at 8:30 AM EST . During the... Read More

NEW YORK , June 28, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it received a written notice (the "Extension Notice") from the Nasdaq Stock Market LLC ("Nasdaq") granting the Company a 180-day extension to regain compliance with... Read More

Dr. Lishan Aklog , PAVmed CEO, to participate in Fireside Chat with Maxim's Anthony Vendetti on Wednesday, June 21, 2023 , at 1:30 PM ET . NEW YORK , June 14, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, announced today that the Company's Chairman and Chief... Read More

NEW YORK , June 2, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced its participation as a founding member of CancerX – a public-private partnership co-hosted by Moffitt Cancer Center... Read More

Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , May 5, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Wednesday, May 17, 2023 , at 8:30 AM EST . During the... Read More

Manning Brings Vast Digital Health Experience Focused on Demonstrable Growth and Commercial Excellence NEW YORK , April 25, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced the... Read More

Company presenting at highly influential HIMSS23 Global Health Conference, today, April 19, 2023 from 11:30 a.m. to 12:30 p.m. CDT . Meta-analysis shows Remote Patient Monitoring delivers improved quality of care, enhances the patient experience, reduces healthcare costs, and improves provider satisfaction NEW YORK , April 19, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed"), a diversified commercial-stage... Read More

NEW YORK , April 17, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that Dr. Lishan Aklog , Chairman and Chief Executive Officer; and Dennis McGrath , Chief Financial Officer will present at the 22 nd Annual Needham Healthcare... Read More

Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , March 3, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Wednesday, March 15, 2023 , at 8:30 AM EST . During the... Read More

Remote patient monitoring of first cohort of cancer patients using VerisBox ™ connected devices and Veris CCP smartphone app initiated Cancer care team utilizing physiologic data and patient reported symptoms delivered to cloud-based Veris CCP clinician portal for real-time optimized personalized care NEW YORK , Feb. 28, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed"), a diversified commercial-stage... Read More

Strategic resource reallocation, including workforce reduction and other cost-cutting measures, to prioritize near-term Lucid and Veris Health commercialization efforts Conference call to be held today at 4:30PM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned... Read More

Companies to host Conference Call at 4:30 PM EDT on Tuesday, January 17, 2023 PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiaries Lucid Diagnostics Inc. (Nasdaq: LUCD), a commercial-stage cancer prevention diagnostics company, and Veris Health Inc., a digital health company... Read More

License option and joint R&D agreement seek to apply Novosound’s groundbreaking flexible thin-film ultrasound technology to intravascular imaging PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (“PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has entered into a license option and joint research and development agreement... Read More

Executes first commercial contract with leading New Jersey oncology practice NEW YORK--( BUSINESS WIRE )-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (“PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that its majority-owned digital health subsidiary Veris Health Inc. (“Veris”), has commercially launched its Veris Cancer... Read More